scout

September 2016

Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma

ByVivek N. Patel, MD,Felix M. Chinea, MD,Deukwoo Kwon, PhD,Gustavo Fernandez, MD,Hanmath J Neboori, MD,Michael A. Samuels, MD,Laura M. Freedman, MD,Nagy M. Elsayad,Donald Weed, MD,Elizabeth Franzmann, MD,Chukwuemeka V. Ikpeazu, MD, PhD,Matthew C. Abramowitz, MD

This study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.

Radiotherapy in the Modern Era in the Management of Langerhans Cell Histiocytosis

ByRupen Garg, BS,Qinyu Chen, MHS,Yin Zhang, PhD,Ariel E. Marciscano, MD,Jing Zeng, MD,Robert J. Arceci, MD, PhD,Stephanie A. Terezakis, MD

Intensity-modulated radiotherapy reduces the mean radiation dose delivered to critical normal structures and should be considered in Langerhans cell histiocytosis treatment when radiotherapy is indicated, particularly given the expected, long-term survival of these patients.